Patents by Inventor Nozer M. Mehta
Nozer M. Mehta has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140249085Abstract: Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent.Type: ApplicationFiled: October 4, 2013Publication date: September 4, 2014Applicant: UGP THERAPEUTICS, INC.Inventors: Nozer M. Mehta, James P. Gilligan
-
Patent number: 8815583Abstract: Cell lines are provided for expressing peptidylglycine alpha-amidating monooxygenase (PAM), or one of its two catalytic domains. High levels of enzyme expression are achieved while utilizing a non-animal source, low protein tissue culture medium. A robust two-step downstream purification results in high enzyme purity. Resulting PAM, or its PHM catalytic domain, is used to catalyze the enzymatic conversion of X-Gly to X-alpha-hydroxy-Gly or X—NH2 (X being a peptide or any chemical compound having a carbonyl group to which a glycine group can be covalently attached). Methods of preparing preferred cell lines are also set forth.Type: GrantFiled: June 23, 2006Date of Patent: August 26, 2014Assignee: Enteris BioPharma, Inc.Inventors: Duncan A. Miller, Nozer M Mehta, Angelo P Consalvo
-
Publication number: 20140073561Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: June 28, 2013Publication date: March 13, 2014Applicant: UPG Therapeutics, Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern
-
Patent number: 8497347Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: July 9, 2012Date of Patent: July 30, 2013Assignee: UGP Therapeutics, Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20130072446Abstract: Polypeptides having homology to regions of the N-terminal 50 residues of human Annexin 1 are provided for medical use as anti-inflammatory agents. Some of the polypeptides have homology to the N-terminal 48 residues of human Annexin 1, especially to residues 2-48 and 11-48 thereof. In some embodiments, properties of these compounds are improved by at least one modification at residues corresponding to residues 11, 22, 25 and/or 36 of human Annexin 1, and/or by C-terminal amidation of the polypeptide. Analogs of amino acids 2-26 of human Annexin 1, especially acetylated at the N-terminus and/or amidated at the C-terminus and having modifications at 11 and/or 22 are also disclosed for medical use as anti-inflammatory agents.Type: ApplicationFiled: June 15, 2012Publication date: March 21, 2013Applicant: UNIGENE LABORATORIES, INC.Inventors: ANGELO P. CONSALVO, NOZER M. MEHTA, MAURO PERRETTI, JESMOND DALLI
-
Patent number: 8378067Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: November 14, 2011Date of Patent: February 19, 2013Assignee: Unigene LaboratoriesInventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20130034897Abstract: Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special universal cloning vectors are provided for the preparation of expression vectors which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.Type: ApplicationFiled: July 9, 2012Publication date: February 7, 2013Applicant: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Angelo P. Consalvo, Martha V.L. Ray, Christopher P. Meenan
-
Publication number: 20120328666Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing targeted release of the peptide to the intestine by combining the composition with an absorption enhancer. Bioavailability is further significantly increased by administering the composition in an acid-resistant protective vehicle which transports components of the invention through the stomach. The composition may optionally further include a sufficient amount of a pH-lowering agent to lower local intestinal pH. All components are released together into the intestine with the peptide.Type: ApplicationFiled: August 26, 2011Publication date: December 27, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
-
Publication number: 20120302497Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: July 9, 2012Publication date: November 29, 2012Applicant: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Patent number: 8252580Abstract: Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special universal cloning vectors are provided for the preparation of expression vectors which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: August 28, 2012Assignee: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Angelo P. Consalvo, Martha V. L. Ray, Christopher P. Meenan
-
Patent number: 8227241Abstract: Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special universal cloning vectors are provided for the preparation of expression vectors which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.Type: GrantFiled: March 9, 2005Date of Patent: July 24, 2012Assignee: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Angelo P. Consalvo, Martha V. L. Ray, Christopher P. Meenan
-
Publication number: 20120183582Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing an active peptide that is amidated at a site that is not naturally amidated.Type: ApplicationFiled: January 2, 2012Publication date: July 19, 2012Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
-
Patent number: 8217139Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: November 14, 2011Date of Patent: July 10, 2012Assignee: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Patent number: 8216822Abstract: Expression systems are disclosed for the direct expression of peptide products into the culture media where genetically engineered host cells are grown. High yield was achieved with a special selection of hosts, and/or fermentation processes which include careful control of cell growth rate, and use of an inducer during growth phase. Special universal cloning vectors are provided for the preparation of expression vectors which include control regions having multiple promoters linked operably with coding regions encoding a signal peptide upstream from a coding region encoding the peptide of interest. Multiple transcription cassettes are also used to increase yield. The production of amidated peptides using the expression systems is also disclosed.Type: GrantFiled: October 30, 2007Date of Patent: July 10, 2012Assignee: Unigene Laboratories, Inc.Inventors: Nozer M. Mehta, Angelo P. Consalvo, Martha V. L. Ray, Christopher P. Meenan
-
Publication number: 20120149635Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: November 14, 2011Publication date: June 14, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Publication number: 20120142586Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: ApplicationFiled: November 14, 2011Publication date: June 7, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan
-
Patent number: 8163871Abstract: Conversion in vitro of X-Gly to X-alpha-hydroxy-Gly or X-NH2 (X being a peptide or any other compound having a carbonyl group capable of forming a covalent bond with glycine) is accomplished enzymatically in the presence of keto acids, or salts or esters thereof, to provide a good yield without the necessity of catalase or similar enzymatic reaction enhancers. Peptidylglycine ?-amidating monooxygenase (PAM) is a preferred enzyme for catalyzing the conversion. Alternatively, peptidylglycine ?-hydroxylating monooxygenase (PHM) is utilized to convert X-Gly to X-alpha-hydroxy-Gly which may be recovered, or optionally may be simultaneously or sequentially converted to an amide by either a Lewis base or action of the enzyme peptidyl ?-hydroxyglycine ?-amidating lyase (PAL). Both PHM and PAL are functional domains of PAM.Type: GrantFiled: September 22, 2008Date of Patent: April 24, 2012Assignee: Unigene Laboratories, Inc.Inventors: Angelo P. Consalvo, Nozer M. Mehta, William Stern, James P. Gilligan
-
Publication number: 20120071410Abstract: Calcitonin products and therapies for treating inflammatory or degenerative diseases are disclosed herein. The pharmaceutical compositions disclosed herein include a first therapeutic agent that is calcitonin, in free or salt form; a second therapeutic agent selected from the group consisting of a protease inhibitor, an antibiotic, a non-steroidal anti-inflammatory agent, a COX-2 inhibitor and a steroidal anti-inflammatory agent other than glucocorticoid; and a pharmaceutically acceptable excipient, carrier or diluent.Type: ApplicationFiled: September 21, 2011Publication date: March 22, 2012Applicant: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, James P. Gilligan
-
Patent number: 8088734Abstract: Bioavailability of peptide active agents to be administered orally is enhanced by a pharmaceutical composition providing an active peptide that is amidated at a site that is not naturally amidated.Type: GrantFiled: January 20, 2004Date of Patent: January 3, 2012Assignee: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, William Stern, James P. Gilligan
-
Patent number: 8076291Abstract: The present invention provides peptides and pharmaceutical compositions thereof for appetite suppression and weight control. Preferred peptides are calcitonin analogs, preferably with specific amino acid changes to make the peptide more amylin-like.Type: GrantFiled: January 22, 2010Date of Patent: December 13, 2011Assignee: Unigene Laboratories Inc.Inventors: Nozer M. Mehta, Amy Sturmer, William Stern, James P. Gilligan